(Q46892598)

26 December 2017

title

Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients (English)

1 reference

26 December 2017

author name string

J H Ku

1

1 reference

26 December 2017

C W Jeong

2

1 reference

26 December 2017

Y H Park

3

1 reference

26 December 2017

M C Cho

4

1 reference

26 December 2017

C Kwak

5

1 reference

26 December 2017

H H Kim

6

1 reference

26 December 2017

publication date

12 October 2010

1 reference

26 December 2017

Prostate Cancer and Prostatic Diseases

published in

1 reference

26 December 2017

volume

14

1 reference

26 December 2017

issue

1

1 reference

26 December 2017

page(s)

63-68

1 reference

26 December 2017

https://scigraph.springernature.com/pub.10.1038/pcan.2010.39

exact match

0 references

cites work

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

Statins and the risk of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

Statins and cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

The influence of statin medications on prostate-specific antigen levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

Statin drugs and risk of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

Statin use and risk of prostate cancer in the California Men's Health Study cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

Statins and prostate cancer risk: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

Cancer risk among statin users: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

Statin use and risk of prostate cancer: results from a population-based epidemiologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

Statin use and risk of prostate cancer recurrence in men treated with radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

Is statin use associated with prostate cancer aggressiveness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

A Streamlined Three-Dimensional Volume Estimation Method Accurately Classifies Prostate Tumors by Volume

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

The Risk of Cancer in Users of Statins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

Long-term follow-up of the West of Scotland Coronary Prevention Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.39

31 March 2020

Identifiers

DOI

10.1038/PCAN.2010.39

1 reference

26 December 2017

1 reference

26 December 2017